<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36168555</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Risk of Long COVID in People Infected With Severe Acute Respiratory Syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease 2019 Vaccine: Community-Based, Matched Cohort Study.</ArticleTitle><Pagination><StartPage>ofac464</StartPage><MedlinePgn>ofac464</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofac464</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofac464</ELocationID><Abstract><AbstractText>We investigated long COVID incidence by vaccination status in a random sample of UK adults from April 2020 to November 2021. Persistent symptoms were reported by 9.5% of 3090 breakthrough severe acute respiratory syndrome coronavirus 2 infections and 14.6% of unvaccinated controls (adjusted odds ratio, 0.59 [95% confidence interval, .50-.69]), emphasizing the need for public health initiatives to increase population-level vaccine uptake.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ayoubkhani</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6352-0394</Identifier><AffiliationInfo><Affiliation>Health Analysis and Life Events Division, Office for National Statistics, Newport, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosworth</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Health Analysis and Life Events Division, Office for National Statistics, Newport, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Sasha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Methodology and Quality Directorate, Office for National Statistics, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pouwels</LastName><ForeName>Koen B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glickman</LastName><ForeName>Myer</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Health Analysis and Life Events Division, Office for National Statistics, Newport, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nafilyan</LastName><ForeName>Vah&#xe9;</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-0160-217X</Identifier><AffiliationInfo><Affiliation>Health Analysis and Life Events Division, Office for National Statistics, Newport, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Public Health, Environment and Society, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaccardi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khunti</LastName><ForeName>Kamlesh</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2343-7099</Identifier><AffiliationInfo><Affiliation>Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alwan</LastName><ForeName>Nisreen A</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0000-0002-4134-8463</Identifier><AffiliationInfo><Affiliation>School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Applied Research Collaboration Wessex, Southampton, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>A Sarah</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID condition</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. K. K. chairs the long COVID research-funded group reporting to the Chief Medical Officer, chairs the Ethnicity Subgroup of the UK Scientific Advisory Group for Emergencies (SAGE), and is a member of SAGE. All other authors report no potential conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36168555</ArticleId><ArticleId IdType="pmc">PMC9494414</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofac464</ArticleId><ArticleId IdType="pii">ofac464</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Office for National Statistics . Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 6 January 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/6january2022. Accessed 10 May 2022.</Citation></Reference><Reference><Citation>Wei &#xa0;J, Pouwels &#xa0;KB, Stoesser &#xa0;N, et al. &#xa0;SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general population. medRxiv [Preprint]. Posted online 14 January 2022. doi:10.1101/2021.09.13.21263487</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.09.13.21263487</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyre &#xa0;DW, Taylor &#xa0;D, Purver &#xa0;M, et al. &#xa0;The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmission. medRxiv [Preprint]. Posted online 15 October 2021. doi:10.1101/2021.09.28.21264260</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.09.28.21264260</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli &#xa0;M, Penfold &#xa0;RS, Merino &#xa0;J, et al. &#xa0;Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis &#xa0;2022; 22:43&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet &#xa0;M, Dercon &#xa0;Q, Harrison &#xa0;PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun &#xa0;2022; 103:154&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>
UK Government . Coronavirus (COVID-19) in the UK. https://coronavirus.data.gov.uk. Accessed 25 January 2022.</Citation></Reference><Reference><Citation>
Office for National Statistics . Coronavirus and vaccination rates in people aged 18 years and over by socio-demographic characteristic and occupation, England: 8 December 2020 to 31 December 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthinequalities/bulletins/coronavirusandvaccinationratesinpeopleaged18yearsandoverbysociodemographiccharacteristicandoccupationengland/8december2020to31december2021. Accessed 10 May 2022.</Citation></Reference><Reference><Citation>Pritchard &#xa0;E, Matthews &#xa0;PC, Stoesser &#xa0;N, et al. &#xa0;Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med &#xa0;2021; 27:1370&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363500</ArticleId><ArticleId IdType="pubmed">34108716</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin &#xa0;PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med &#xa0;2009; 28:3083&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly &#xa0;Z, Bowe &#xa0;B, Xie &#xa0;Y. Long Covid after breakthrough COVID-19: the post-acute sequelae of breakthrough COVID-19. Research Square [Preprint]. 2021. doi:10.21203/rs.3.rs-1062160/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1062160/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker &#xa0;AJ, MacKenna &#xa0;B, Inglesby &#xa0;P, et al. &#xa0;Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. Br J Gen Pract &#xa0;2021; 71:e806&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340730</ArticleId><ArticleId IdType="pubmed">34340970</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson &#xa0;EJ, Williams &#xa0;DM, Walker &#xa0;AJ, et al. &#xa0;Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun &#xa0;2022; 13:3528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantelic &#xa0;M, Ziauddeen &#xa0;N, Boyes &#xa0;M, et al. &#xa0;Long Covid stigma: estimating burden and validating scale in a UK-based sample. medRxiv [Preprint]. Posted online 26 May 2022. doi:10.1101/2022.05.26.22275585</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.05.26.22275585</ArticleId><ArticleId IdType="pmc">PMC9683629</ArticleId><ArticleId IdType="pubmed">36417364</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis &#xa0;HE, Assaf &#xa0;GS, McCorkell &#xa0;L, et al. &#xa0;Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine &#xa0;2021; 38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>